A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Akeso
- Target Recruit Count
- 130
- Registration Number
- NCT03866967
- Locations
- 🇨🇳
FuDan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
Phase 3
Terminated
- Conditions
- Lung Cancer Non-small Cell Stage IV
- Interventions
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Akeso
- Target Recruit Count
- 164
- Registration Number
- NCT03866980
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
🇨🇳Shanghai Chest Hospital, Shanghai, Shanghai, China
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma
Phase 1
Completed
- Conditions
- Gastric AdenocarcinomaAdvanced Solid TumorsGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Akeso
- Target Recruit Count
- 338
- Registration Number
- NCT03852251
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma
Phase 1
Completed
- Conditions
- Hodgkin's Lymphoma
- Interventions
- Biological: AK105
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Akeso
- Target Recruit Count
- 94
- Registration Number
- NCT03722147
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beiing, China
© Copyright 2025. All Rights Reserved by MedPath